New strategies in the treatment of refractory forms and relapses of follicular lymphoma: CAR T-cell therapy
https://doi.org/10.35754/0234-5730-2025-70-2-252-263
Abstract
Introduction. Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the long overall survival, the tumor remains incurable in most patients. Currently, there is no specific algorithm for choosing therapy for ≥3 lines of patients with FL. CAR T-cell therapy (therapy with genetically modified T-lymphocytes carrying a chimeric antigen receptor — CAR) has proven effective in many tumors, including FL.
Aim. to systematize data on the efficacy and safety of modern CAR T-cell therapy for follicular lymphoma.
Main findings. CAR T-cell therapy is an effective option both for patients with FL after multiple courses of therapy, and for refractory tumors. Ongoing advancements continue to refine this method, enhancing its safety and expanding the possibilities of use. CAR T-cell therapy is increasingly being integrated into anti-relapse regimens for FL.
Supporting agencies: the study was performed in accordance with the State Assignment ‘Study of efficacy and safety of CAR T lymphocytes of the 2nd generation, specifi c to CD19 antigen of B-cells, in adult patients with relapsed and refractory forms of B-cell lymphoproliferative diseases’ № 124012300248-3
About the Authors
A. K. Smolyaninova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Anna K. Smolianinova - Cand. Sci. (Med.), Hematologist, Department of Hematology and Chemotherapy of Lymphomas with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit.
Moscow
O. A. Aleshina
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Olga A. Aleshina - Cand. Sci. (Med.), Head of cell and immunotherapy department.
Moscow
A. V. Bogolyubova
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Apolinaria V. Bogolyubova - Cand. Sci. (Biol.), Head of Laboratory of transplantation immunology.
Moscow
E. E. Zvonkov
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Evgeny E. Zvonkov - Dr. Sci. (Med.), Head of the Department of Hematology and Chemotherapy of Lymphomas with Bone Marrow and Hematopoietic Stem Cell Transplantation Unit.
Moscow
References
1. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–76. DOI: 10.1182/blood-2005-06-2508.
2. Watanabe T., Tobinai K., Wakabayashi M., et al. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203. Br J Haematol. 2024;204(3):849–60. DOI: 10.1111/bjh.19213.
3. Ghione P., Palomba M.L., Ghesquieres H., et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108(3):822–32. DOI: 10.3324/HAEMATOL.2022.281421.
4. Casulo C., Dixon J.G., Le-Rademacher J., et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–93. DOI: 10.1182/blood.2020010263.
5. Metzner B., Pott C., Müller T.H., et al. Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation. Eur J Haematol. 2021;107(5):543–52. DOI: 10.1111/ejh.13691.
6. Jiménez-Ubieto A., Grande C., Caballero D., et al. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–40. DOI: 10.1016/j.bbmt.2017.05.021.
7. Smolyaninova A.K., Belyayeva A. V., Sidorova Y. V., et al. High-dose chemotherapy with transplantation of autologous hematopoietic stem cells in the fi rst line of follicular lymphoma therapy. Gematologiya I Transfusiologiya. 2023;68(3):344– 62 (In Russian). DOI: 10.35754/0234-5730-2023-68-3-344-362.
8. Giraudo M., Jackson Z., Das I., et al. Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma. Pathogens and Immunity. 2024;9(1):1–17. DOI: 10.20411/pai.v9i1.647.
9. Gavrilina O.A., Galstyan G.M., Shchekina A.E., et al. Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. Gematologiya I Transfusiologiya. 2022;67(1):8–28 (In Russian). DOI: 10.35754/02345730-2022-67-1-8-28.
10. Jacobs R., Jacobson C. The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Front Oncol. 2024;14: 1384600. DOI: 10.3389/fonc.2024.1384600.
11. Fowler N.H., Chavez J.C., Riedell P.A. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024;19(4):495–510. DOI: 10.1007/s11523-024-01070-z.
12. Thiruvengadam S.K., Shouse G., Danilov A. V. Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma. Blood Rev. 2023;61:101099. DOI: 10.1016/j.blre.2023.101099.
13. Perica K., Curran K.J., Brentjens R.J., et al. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135–41. DOI: 10.1016/j.bbmt.2018.02.018.
14. Ayala Ceja M., Khericha M., Harris C.M., et al. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903. DOI: 10.1084/jem.20230903.
15. Lickefett B., Chu L., Ortiz-Maldonado V., et al. Lymphodepletion — an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935. DOI: 10.3389/fimmu.2023.1303935.
16. Chong E.A., Chong E.R., Therwhanger D., et al. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplant Cell Ther. 2024;30(7):726.e1–e8. DOI: 10.1016/j.jtct.2024.03.015.
17. Ghilardi G., Chong E.A., Svoboda J., et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33(9):916–28. DOI: 10.1016/j.annonc.2022.05.521.
18. Eshhar Z., Waks T., Gross G., et al. Specifi c activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Nat Acad Sci. 1993;90(2):720–4. DOI: 10.1073/pnas.90.2.720.
19. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifi ed autologous CD20-specifi c T cells. Blood. 2008;112(6):2261–71. DOI: 10.1182/blood-2007-12-128843.
20. Kershaw M.H., Westwood J.A., Parker L.L., et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modifi ed T Cells for Ovarian Cancer. Clin Cancer Res. 2006;12(20):6106–15. DOI: 10.1158/1078-0432.CCR-06-1183.
21. van der Stegen S.J.C., Hamieh M., Sadelain M. The pharmacology of secondgeneration chimeric antigen receptors. Nat Rev Drug Disccov. 2015;14(7):499– 509. DOI: 10.1038/nrd4597.
22. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modifi ed T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–6. DOI: 10.1172/JCI46110.
23. Abramson J.S., Palomba M.L., Gordon L.I., et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839– 52. DOI: 10.1016/S0140-6736(20)31366-0.
24. Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42. DOI: 10.1056/NEJMOA1914347.
25. Locke F.L., Ghobadi A., Jacobson C.A., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. DOI: 10.1016/S1470-2045(18)30864-7.
26. Schuster S.J., Bishop M.R., Tam C.S., et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45– 56. DOI: 10.1056/nejmoa1804980.
27. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102. DOI: 10.1182/BLOOD-2010-04-281931.
28. Cappell K.M., Sherry R.M., Yang J.C., et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020;38(32):3805–15. DOI: 10.1200/JCO.20.01467.
29. Schuster S.J., Svoboda J., Chong E.A., et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545–54. DOI: 10.1056/NEJMoa1708566.
30. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9. DOI: 10.1200/JCO.2014.56.2025.
31. Jacobson C.A., Chavez J.C., Sehgal A.R., et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. DOI: 10.1016/s1470-2045(21)00591-X.
32. Schuster S.J., Fowler N., Dickinson M., et al. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up. Blood. 2023;142(Suppl. 1):601. DOI: 10.1182/blood-2023-180936.
33. Solal-Celigny P. Follicular Lymphoma International Prognostic Index. Blood. 2004;104(5):1258–65. DOI: 10.1182/blood-2003-12-4434.
34. Neelapu S.S., Chavez J.C., Sehgal A.R., et al. Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood. 2023;142(Supplement 1):4868. DOI: 10.1182/blood-2023-174914.
35. Zelenetz A.D., Gordon L.I., Abramson J.S., et al. NCCN Guidelines Insights: BCell Lymphomas, Version 3.2019. J Natl Compr Cancer Netw. 2019;17(6):650– 61. DOI: 10.6004/jnccn.2019.0029.
36. Fowler N.H., Dickinson M., Dreyling M., et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–32. DOI: 10.1038/s41591-021-01622-0.
37. Mor V., Laliberte L., Morris J.N., et al. The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7. DOI: 10.1002/1097-0142(19840501)53:9<2002::AIDCNCR2820530933>3.0.CO;2-W.
38. Azoulay É., Castro P., Maamar A., et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021;8(5):e355–64. DOI: 10.1016/S2352-3026(21)00060-0.
39. Щекина А.Е., Галстян Г.М., Гаврилина О.А., и др.. Синдром высвобождения цитокинов и другие осложнения после терапии Т-лимфоцитами с химерным антигенным рецептором у взрослых с В-клеточными лимфомами и лейкозами. Гематология и трансфузиология. 2022;67(S2.):88.
40. Neelapu S.S., Tummala S., Kebriaei P., et al. Chimeric antigen receptor Tcell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. DOI: 10.1038/nrclinonc.2017.148.
41. Kymriah® (tisagenlecleucel) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2022.
42. Yescarta® (axicabtagene ciloleucel) [package insert]. Santa Monica (CA): Kite Pharma, Inc.; 2022.
43. Adkins, S. CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2019;10(Suppl 3): 21–28. DOI: 10.6004/jadpro.2019.10.4.11.
44. Jacobson C.A., Hemmer M.T., Hu Z.-H., et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):7509. DOI: 10.1200/JCO.2023.41.16_suppl.7509.
45. Ghafouri S., Fenerty K., Schiller G., et al. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2021;21(12):861–72. DOI: 10.1016/j.clml.2021.07.002.
46. Kwon M., Iacoboni G., Reguera J.L., et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2022;108(1):110–21. DOI: 10.3324/haematol.2022.280805.
47. Dickinson M., Martinez-Lopez J., Jousseaume E., et al. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymph. 2024;65(3):323–32. DOI: 10.1080/10428194.2023.2289854.
48. Flinn I.W., Jacobson C.A., Nastoupil L.J., et al. ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-ofcare therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):TPS7579. DOI: 10.1200/JCO.2023.41.16_suppl.TPS7579.
49. Ghione P., Palomba M.L., Patel A.R., et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–60. DOI: 10.1182/blood.2021014375.
50. Salles G., Schuster S.J., Dreyling M., et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835–43. DOI: 10.1182/bloodadvances.2022008150.
51. Visco C., Chiappella A., Nassi L., et al. Rituximab, bendamustine, and lowdose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4(1):e15–23. DOI: 10.1016/S2352-3026(16)30185-5.
52. Neelapu S.S., Chavez J., Sehgal A.R., et al. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood. 2022;140(Supplement 1):10380–3. DOI: 10.1182/blood-2022-156120.
53. Iacoboni G., Navarro V., Martín-López A.Á., et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2024;42(2):205–17. DOI: 10.1200/JCO.23.01097.
54. Yakoub-Agha I., Chabannon C., Bader P., et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316. DOI: 10.3324/haematol.2019.229781.
55. Casulo C., Friedberg J.W., Ahn K.W., et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–71. DOI: 10.1016/j.bbmt.2017.12.771.
56. Locke F.L., Miklos D.B., Jacobson C.A., et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640– 54. DOI: 10.1056/NEJMoa2116133.
57. Shadman M., Caimi P.F., O’Brien S.M., et al. Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial. Blood. 2023;142(Suppl. 1):2102. DOI: 10.1182/blood-2023-175007.
58. Shah N.N., Johnson B.D., Schneider D., et al. Bispecifi c anti-CD20, antiCD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Med. 2020;26(10):1569–75. DOI: 10.1038/s41591-020-1081-3.
59. Tong C., Zhang Y., Liu Y., et al. Optimized tandem CD19/CD20 CARengineered T cells in refractory/relapsed B cell lymphoma. Blood. 2020; 135 (14):1632–44. DOI: 10.1182/blood.2020005278.
60. Locke F.L., Munoz J.L., Tees M.T., et al. ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas. Blood. 2023;142 (Suppl. 1):2095. DOI: 10.1182/blood-2023-189196
Review
For citations:
Smolyaninova A.K., Aleshina O.A., Bogolyubova A.V., Zvonkov E.E. New strategies in the treatment of refractory forms and relapses of follicular lymphoma: CAR T-cell therapy. Russian journal of hematology and transfusiology. 2025;70(2):252-263. (In Russ.) https://doi.org/10.35754/0234-5730-2025-70-2-252-263
Views:
43
Email this article 
